Advertisement
Canada markets open in 8 hours 14 minutes

  • S&P/TSX

    21,581.35
    +64.45 (+0.30%)
     

  • S&P 500

    5,473.17
    -13.86 (-0.25%)
     

  • DOW

    39,134.76
    +299.90 (+0.77%)
     

  • CAD/USD

    0.7313
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    82.34
    +0.17 (+0.21%)
     

  • Bitcoin CAD

    88,210.12
    -1,064.79 (-1.19%)
     

  • CMC Crypto 200

    1,354.79
    -27.87 (-2.02%)
     

  • GOLD FUTURES

    2,376.10
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,017.39
    -7.84 (-0.39%)
     

  • 10-Yr Bond

    4.2540
    +0.0370 (+0.88%)
     

  • NASDAQ futures

    19,804.00
    +40.75 (+0.21%)
     

  • VOLATILITY

    13.28
    +0.80 (+6.41%)
     

  • FTSE

    8,272.46
    +67.35 (+0.82%)
     

  • NIKKEI 225

    38,638.06
    +5.04 (+0.01%)
     

  • CAD/EUR

    0.6819
    -0.0002 (-0.03%)
     

Revvity to Present at Goldman Sachs Global Healthcare Conference

Business Wire
·1 min read

WALTHAM, Mass., May 28, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL.

Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here.

A live audio webcast will be available on the Events section of the Company’s website at www.revvity.com. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days.

About Revvity

At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

ADVERTISEMENT

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528846410/en/

Contacts

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Media Relations:
Chet Murray
(781) 663-5719
chet.murray@revvity.com